Fluphenazine Decanoate

2020 ◽  
Author(s):  
Keyword(s):  
Fluphenazine Decanoate

Evaluation of Inpatient Depot Antipsychotic Prescribing

1996 ◽  
Vol 30 (12) ◽  
pp. 1381-1386 ◽  
Author(s):  
Dennis J Pabis ◽  
Peter G Dorson ◽  
M Lynn Crismon
Keyword(s):  
Length Of Stay ◽  
Product Information ◽  
Length Of Hospital Stay ◽  
Inpatient Setting ◽  
Pharmacy Staff ◽  
Antipsychotic Therapy ◽  
Fluphenazine Decanoate ◽  
Short Acting ◽  
Depot Antipsychotic ◽  
Depot Therapy

OBJECTIVE: To assess the use of fluphenazine decanoate and haloperidol decanoate in an inpatient setting. DESIGN: A prospective observational study conducted over a 3-month period. SETTING: A 400-bed state psychiatric hospital. INTERVENTIONS: The psychiatric pharmacy staff evaluated the medical records and new orders of 30 consecutive patients receiving depot antipsychotic formulations using a detailed evaluation form and the hospital pharmacy computer database. Criteria for evaluation were derived from the medical literature and product information, and included the following areas: diagnosis, stabilization on a short-acting form of the antipsychotic, appropriateness of dosage conversion to depot therapy, concomitant administration of short-acting antipsychotics (and duration of concomitant medications), and plasma concentration monitoring. RESULTS: Only 7 patients (23%) received what would be considered optimal depot antipsychotic therapy. These patients were receiving a stable dosage of a short-acting antipsychotic prior to conversion to depot therapy (i.e., ≥7 d), received optimal dose conversion to a depot form, and received optimum overlap with a short-acting preparation (i.e., overlap ≤7 d with fluphenazine HCl and 7–30 d with haloperidol HCl). When length of stay data were evaluated, no significant differences were observed in patients who received optimal therapy versus those who did not. There was also no difference in length of stay when the study group was compared with an age-, sex-, and diagnosis-matched cohort group. However, quantitatively fewer adverse effects were reported for patients whose treatment was considered optimal on the basis of the evaluation criteria. CONCLUSIONS: Depot antipsychotic therapy frequently did not meet the criteria for optimal use. This did not affect length of hospital stay in these individuals. However, individuals who met the criteria experienced quantitatively fewer adverse events.

Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism

1972 ◽  
Vol 2 (4) ◽  
pp. 406-413 ◽  
Author(s):  
R. H. S. Mindham ◽  
R. Gaind ◽  
B. H. Anstee ◽  
Lorna Rimmer
Keyword(s):  
Nervous System ◽  
Practical Importance ◽  
Clinical Signs ◽  
Drug Induced ◽  
Double Blind ◽  
Fluphenazine Decanoate ◽  
Cholinergic Drugs ◽  
Blind Comparison ◽  
Pharmacologically Active ◽  
Active Substances

SynopsisA double-blind comparison was made of the effects of amantadine hydrochloride, orphenadrine hydrochloride, and placebo in the control of the effects on the extrapyramidal nervous system of fluphenazine decanoate. Patients were assessed with regard to the main symptoms of Parkinsonism, the leading clinical signs, performance in walking, writing and squeezing, changes in mood, and unwanted effects of medication. Neither of the pharmacologically active substances was superior to placebo. Attention is drawn to the paucity of evidence for the effectiveness of anti-cholinergic drugs in both Parkinson's disease and in drug-induced Parkinsonism. The special difficulties in performing trials of substances used in relieving the unwanted effects of other drugs are discussed in relationship to defects in methodology in both this and earlier trials. The findings of the present study are not conclusive but show a clear need for further research in this field. The possible theoretical and practical importance of such research is discussed.

DOUBLE-BLIND TRIAL OF FLUPHENAZINE DECANOATE

The Lancet ◽  
1972 ◽  
Vol 300 (7776) ◽  
pp. 543-544 ◽  
Author(s):  
StephenH. Curry ◽  
Leslie Adamson
Keyword(s):  
Double Blind Trial ◽  
Double Blind ◽  
Fluphenazine Decanoate ◽  
Blind Trial

scholarly journals Effect of 1050 mg fluphenazine decanoate given intramuscularly over six days.

BMJ ◽  
1983 ◽  
Vol 286 (6370) ◽  
pp. 1016-1017 ◽  
Author(s):  
H K Cheung ◽  
E C Yu
Keyword(s):  
Fluphenazine Decanoate
Sign in / Sign up

Export Citation Format

Share Document